Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 651

1.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD.

AIDS. 2004 Nov 19;18(17):2277-84.

PMID:
15577540
2.

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.

Clin Infect Dis. 2005 Oct 15;41(8):1186-95. Epub 2005 Sep 13.

PMID:
16163639
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.

Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T.

J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):236-45.

PMID:
10839659
6.

Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.

Langmann P, Zilly M, Weissbrich B, Schlör C, Väth T, Richter E, Klinker H.

Eur J Med Res. 2000 Feb 28;5(2):59-62.

PMID:
10720564
7.

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.

Gisolf EH, Enting RH, Jurriaans S, de Wolf F, van der Ende ME, Hoetelmans RM, Portegies P, Danner SA.

AIDS. 2000 Jul 28;14(11):1583-9.

PMID:
10983645
8.

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.

Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE.

AIDS. 1999 Jul 9;13(10):1207-12.

PMID:
10416524
9.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland.; Swiss Mother and Child HIV Cohort Study (MoCHiV)..

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
10.

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team..

HIV Med. 2007 Nov;8(8):529-35.

11.

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.

Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren JD; EuroSIDA study group..

AIDS. 2001 Jan 26;15(2):201-9.

PMID:
11216928
12.

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M.

AIDS. 1998 Sep 10;12(13):1631-7.

PMID:
9764782
13.
14.

The choice of HIV protease inhibitor: indinavir is currently the best option.

[No authors listed]

Prescrire Int. 1999 Apr;8(40):55-60. Review.

PMID:
10848067
15.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

16.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Oldfield V, Plosker GL.

Drugs. 2006;66(9):1275-99. Review.

PMID:
16827606
17.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group..

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
18.

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.

Antivir Ther. 2007;12(8):1237-46.

PMID:
18240863
19.

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.

Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D.

AIDS. 2000 Jan 28;14(2):141-9.

PMID:
10708284
20.

Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.

Salzberger B, Rockstroh J, Wieland U, Franzen C, Schwenk A, Jütte A, Hegener P, Cornely O, Mörchen C, Gaensicke T, Diehl V, Fätkenheuer G.

Eur J Med Res. 1999 Nov 22;4(11):449-55.

PMID:
10585299

Supplemental Content

Support Center